Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies

Journal of Human Genetics

Volumn 59, Issue 1, 2014, Pages 16-23

  Nolis, Tom ^a  

^a Graduate Entry Medical School   (Canada)

Author keywords

Genetics; HIV; lipodystrophy; pathophysiology

Indexed keywords

AMPRENAVIR; CAVEOLIN 1; CCAAT ENHANCER BINDING PROTEIN ALPHA; INSULIN; LAMIN A; LAMIN C; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEINASE INHIBITOR; RECQ HELICASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SMAD3 PROTEIN; STAVUDINE; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR GATA 3; ZIDOVUDINE;

BARRAQUER SIMONS SYNDROME; CONGENITAL GENERALIZED LIPODYSTROPHY; FAMILIAL PARTIAL LIPODYSTROPHY; HEREDITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LAWRENCE SYNDROME; LIPODYSTROPHY; LOSS OF FUNCTION MUTATION; REVIEW;

HUMANS; LIPODYSTROPHY;

EID: 84893216910     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2013.107     Document Type: Review

References (86)

1. Garg, A. & Agarwal, A. K. Lipodystrophies: Disorders of adipose tissue biology. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1791, 507-513 (2009).
2. Garg, A. & Misra, A. Lipodystrophies: Rare disorders causing metabolic syndrome. Endocrinol. Metab. Clin. North Am. 33, 305-331 (2004).
3. Mallewa, J. E., Wilkins, E., Vilar, J., Mallewa, M., Doran, D., Back, D. et al. HIVassociated lipodystrophy: A review of underlying mechanisms and therapeutic options. J. Antimicrob. Chemother. 62, 648-660 (2008).
4. Nagy, G. S., Tsiodras, S., Martin, L. D., Avihingsanon, A., Gavrila, A., Hsu, W. C. et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin. Infect. Dis. 36, 795-802 (2003).
5. Domingo, P., Estrada, V., López-Aldeguer, J., Villaroya, F. & Mart́nez, E. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev. 14, 112-123 (2012).
6. Kershaw, E. E. & Flier, J. S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548-2556 (2004).
7. Agarwal, A. K. & Garg, A. Genetic disorders of adipose tissue development, differentiation, and death. Annu. Rev. Genomics Hum. Genet. 7, 175-199 (2006).
8. Abate, N. Adipocyte maturation arrest: A determinant of systemic insulin resistance to glucose disposal. J. Clin. Endocrinol. Metab. 97, 760-763 (2012).
9. Rosen, E. D. & MacDougald, O. A. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 7, 885-896 (2006).
10. Pei, H., Yao, Y., Yang, Y., Liao, K. & Wu, J. R. Kruppel-like factor KLF9 regulates PPARg transactivation at the middle stage of adipogenesis. Cell Death Differ. 18, 315- 327 (2011).
11. Bertrand, A. T., Chikhaoui, K., Ben, Yaou R. & Bonne, G. [Laminopathies: One gene, several diseases]. Biol. Aujourdhui 205, 147-162 (2011).
12. Van Maldergem, L., Magré, J., Khallouf, T. E., Gedde-Dahl, T. Jr, Delépine, M., Trygstad, O. et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J. Med. Genet. 39, 722-733 (2002).
13. Agarwal, A. K., Simha, V., Oral, E. A., Moran, S. A., Gorden, P., O'Rahilly, S. et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J. Clin. Endocrinol. Metab. 88, 4840-4847 (2003).
14. Pardini, V. C., Victó ria, I. M., Rocha, S. M., Andrade, D. G., Rocha, A. M., Pieroni, F. B. et al. Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatropic diabetes. J. Clin. Endocrinol. Metab. 83, 503-508 (1998).
15. Magre, J., Delépine, M., Van Maldergem, L., Robert, J. J., Maassen, J. A., Meier, M. et al. Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes 52, 1573-1578 (2003).
16. Garg, A., Wilson, R., Barnes, R., Arioglu, E., Zaidi, Z., Gurakan, F. et al. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J. Clin. Endocrinol. Metab. 84, 3390-3394 (1999).
17. Agarwal, A. K., Arioglu, E., De Almeida, S., Akkoc, N., Taylor, S. I., Bowcock, A. M. et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat. Genet. 31, 21-23 (2002).
18. Subauste, A. R., Das, A. K., Li, X., Elliott, B. G., Evans, C., El Azzouny, M. et al. Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations. Diabetes 61, 2922-2931 (2012).
19. Agarwal, A. K. & Garg, A. Congenital generalized lipodystrophy: Significance of triglyceride biosynthetic pathways. Trends Endocrinol. Metab. 14, 214-221 (2003).
20. Simha, V. & Garg, A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J. Clin. Endocrinol. Metab. 88, 5433-5437 (2003).
21. Cartwright, B. R. & Goodman, J. M. Seipin: From human disease to molecular mechanism. J. Lipid Res. 53, 1042-1055 (2012).
22. Payne, V. A., Grimsey, N., Tuthill, A., Virtue, S., Gray, S. L., Dalla Nora, E. et al. The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation. Diabetes 57, 2055-2060 (2008).
23. Yang, W., Thein, S., Guo, X., Xu, F., Venkatesh, B., Sugii, S. et al. Seipin differentially regulates lipogenesis and adipogenesis through a conserved core sequence and an evolutionarily acquired C-terminus. Biochem. J. 452, 37-44 (2013).
24. Kim, C. A., Delépine, M., Boutet, E., El Mourabit, H., Le Lay, S., Meier, M. et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J. Clin. Endocrinol. Metab. 93, 1129-1134 (2008).
25. Hayashi, Y. K., Matsuda, C., Ogawa, M., Goto, K., Tominaga, K., Mitsuhashi, S. et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J. Clin. Invest. 119, 2623-2633 (2009).
26. Mercier, I., Jasmin, J. F., Pavlides, S., Minetti, C., Flomenberg, N., Pestell, R. G. et al. Clinical and translational implications of the caveolin gene family: Lessons from mouse models and human genetic disorders. Lab. Invest. 89, 614-623 (2009).
27. Shastry, S., Delgado, M. R., Dirik, E., Turkmen, M., Agarwal, A. K. & Garg, A. Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. Am. J. Med. Genet. A. 152A, 2245-2253 (2010).
28. Rajab, A., Straub, V., McCann, L. J., Seelow, D., Varon, R., Barresi, R. et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 6, e1000874 (2010).
29. Garg, A. Clinical review: Lipodystrophies: Genetic and acquired body fat disorders. J. Clin. Endocrinol. Metab. 96, 3313-3325 (2011).
30. Pope, E., Janson, A., Khambalia, A. & Feldman, B. Childhood acquired lipodystrophy: A retrospective study. J. Am. Acad. Dermatol. 55, 947-950 (2006).
31. Misra, A. & Garg, A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: Case reports and review of the literature. Medicine (Baltimore) 82, 129-146 (2003).
32. Savage, D. B., Semple, R. K., Clatworthy, M. R., Lyons, P. A., Morgan, B. P., Cochran, E. K. et al. Complement abnormalities in acquired lipodystrophy revisited. J. Clin. Endocrinol. Metab. 94, 10-16 (2009).
33. Misra, A., Peethambaram, A. & Garg, A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: Report of 35 cases and review of the literature. Medicine (Baltimore) 83, 18-34 (2004).
34. Fiorenza, C. G., Chou, S. H. & Mantzoros, C. S. Lipodystrophy: Pathophysiology and advances in treatment. Nat. Rev. Endocrinol. 7, 137-150 (2011).
35. Mathieson, P. W., Wu rzner, R., Oliveria, D. B., Lachmann, P. J. & Peters, D. K. Complement-mediated adipocyte lysis by nephritic factor sera. J. Exp. Med. 177, 1827-1831 (1993).
36. Oswiecimska, J., Ziora, K., Geisler, G. & Dyduch, A. Acquired partial lipodystrophy in an 11-year-old girl. Pediatr. Int. 50, 714-716 (2008).
37. Hegele, R. A., Cao, H., Liu, D. M., Costain, G. A., Charlton-Menys, V., Rodger, N. W. et al. Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. Am. J. Hum. Genet. 79, 383-389 (2006).
38. Garg, A. Acquired and inherited lipodystrophies. N. Engl. J. Med. 350, 1220-1234 (2004).
39. Dunnigan, M. G., Cochrane, M. A., Kelly, A. & Scott, J. W. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Q. J. Med. 43, 33-48 (1974).
40. Kobberling, J. & Dunnigan, M. G. Familial partial lipodystrophy: Two types of an X linked dominant syndrome, lethal in the hemizygous state. J. Med. Genet. 23, 120-127 (1986).
41. Garg, A., Peshock, R. M. & Fleckenstein, J. L. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J. Clin. Endocrinol. Metab. 84, 170-174 (1999).
42. Garg, A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J. Clin. Endocrinol. Metab. 85, 1776-1782 (2000).
43. Vantyghem, M. C., Vincent-Desplanques, D., Defrance-Faivre, F., Capeau, J., Fermon, C., Valat, A. S. et al. Fertility and obstetrical complications in women with LMNArelated familial partial lipodystrophy. J. Clin. Endocrinol. Metab. 93, 2223-2229 (2008).
44. Garg, A., Speckman, R. A. & Bowcock, A. M. Multisystem dystrophy syndrome due to novel missense mutations in the amino-terminal head and alpha-helical rod domains of the lamin A/C gene. Am. J. Med. 112, 549-555 (2002).
45. Subramanyam, L., Simha, V. & Garg, A. (2010)Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A/C mutations. Clin. Genet. 78, 66-73.
46. Peters, J. M., Barnes, R., Bennett, L., Gitomer, W. M., Bowcock, A. M. & Garg, A. Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22. Nat. Genet. 18, 292-295 (1998).
47. Cao, H. & Hegele, R. A. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum. Mol. Genet. 9, 109-112 (2000).
48. Agarwal, A. K. & Garg, A. A novel heterozygous mutation in peroxisome proliferatoractivated receptor-gamma gene in a patient with familial partial lipodystrophy. J. Clin. Endocrinol. Metab. 87, 408-411 (2002).
49. Boguslavsky, R. L., Stewart, C. L. & Worman, H. J. Nuclear lamin A inhibits adipocyte differentiation: Implications for Dunnigan-type familial partial lipodystrophy. Hum. Mol. Genet. 15, 653-663 (2006).
50. Caron, M., Auclair, M., Donadille, B., Béréziat, V., Guerci, B., Laville, M. et al. Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. Cell Death Differ. 14, 1759-1767 (2007).
51. George, S., Rochford, J. J., Wolfrum, C., Gray, S. L., Schinner, S., Wilson, J. C. et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304, 1325-1328 (2004).
52. Rubio-Cabezas, O., Puri, V., Murano, I., Saudek, V., Semple, R. K., Dash, S. et al. LD Screening Consortium. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol. Med. 1, 280- 287 (2009).
53. Gandotra, S., Le Dour, C., Bottomley, W., Cervera, P., Giral, P., Reznik, Y. et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N. Engl. J. Med. 364, 740- 748 (2011).
54. Olofsson, S. O., Bostrom, P., Andersson, L., Rutberg, M., Levin, M., Perman, J. et al. Triglyceride containing lipid droplets and lipid droplet-associated proteins. Curr. Opin. Lipidol. 19, 441-447 (2008).
55. Hegele, R. A., Cao, H., Frankowski, C., Mathews, S. T. & Leff, T. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51, 3586- 3590 (2002).
56. Semple, R. K., Chatterjee, V. K. & O'Rahilly, S. PPAR gamma and human metabolic disease. J. Clin. Invest. 116, 581-589 (2006).
57. Pichierri, P., Ammazzalorso, F., Bignami, M. & Franchitto, A. The Werner syndrome protein: Linking the replication checkpoint response to genome stability. Aging (Albany NY) 3, 311-318 (2011).
58. Doh, Y. J., Kim, H. K., Jung, E. D., Choi, S. H., Kim, J. G., Kim, B. W. et al. Novel LMNA gene mutation in a patient with Atypical Werner's Syndrome. Korean J. Intern. Med. 24, 68-72 (2009).
59. Chun, S. G., Shaeffer, D. S. & Bryant-Greenwood, P. K. The Werner's Syndrome RecQ helicase/exonuclease at the nexus of cancer and aging. Hawaii Med. J. 70, 52-55 (2011).
60. Popuri, V., Huang, J., Ramamoorthy, M., Tadokoro, T., Croteau, D. L. & Bohr, V. A. RECQL5 plays co-operative and complementary roles with WRN syndrome helicase. Nucleic Acids Res. 41, 881-899 (2013).
61. Chen, D., Misra, A. & Garg, A. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. J. Clin. Endocrinol. Metab. 87, 4845- 4856 (2002).
62. Shlay, J. C., Sharma, S., Peng, G., Gibert, C. L. & Grunfeld, C. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA); International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 51, 298-304 (2009).
63. Blumer, R. M., van Vonderen, M. G., Sutinen, J., Hassink, E., Ackermans, M., van Agtmael, M. A. et al. Zidovudine/lamivudine contributes to insulin resistance within months of starting combination antiretroviral therapy. AIDS 22, 227-236 (2008).
64. Pacenti, M., Barzon, L., Favaretto, F., Fincati, K., Romano, S., Milan, G. et al. Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. AIDS 20, 1691-1705 (2006).
65. Lagathu, C., Eustace, B., Prot, M., Frantz, D., Gu, Y., Bastard, J. P. et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir. Ther. 12, 489-500 (2007).
66. Bastard, J. P., Caron, M., Vidal, H., Jan, V., Auclair, M., Vigouroux, C. et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359, 1026-1031 (2002).
67. Murata, H., Hruz, P. W. & Mueckler, M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 275, 20251-20254 (2000).
68. Sievers, M., Walker, U. A., Sevastianova, K., Setzer, B., Wa°gsater, D., Eriksson, P. et al. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy. J. Infect. Dis. 200, 252-262 (2009).
69. Johnson, J. A., Albu, J. B., Engelson, E. S., Fried, S. K., Inada, Y., Ionescu, G. et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am. J. Physiol. Endocrinol. Metab. 286, E261-E271 (2004).
70. Hudon, S. E., Coffinier, C., Michaelis, S., Fong, L. G., Young, S. G. & Hrycyna, C. A. HIV-protease inhibitors block the enzymatic activity of purified Ste24p. Biochem. Biophys. Res. Commun 374, 365-368 (2008).
71. Gibellini, L., De Biasi, S., Pinti, M., Nasi, M., Riccio, M., Carnevale, G. et al. The protease inhibitor atazanavir triggers autophagy and mitophagy in human preadipocytes. AIDS 26, 2017-2026 (2012).
72. Zha, B. S., Wan, X., Zhang, X., Zha, W., Zhou, J., Wabitsch, M. et al. HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes. PLoS One 8, e59514 (2013).
73. Carr, A., Miller, J., Law, M. & Cooper, D. A. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14, F25-F32 (2000).
74. Lee, H., Hanes, J. & Johnson, K. A. Toxicity of nucleoside analogs used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42, 14711-14719 (2003).
75. Divi, R. L., Haverkos, K. J., Humsi, J. A., Shockley, M. E., Thamire, C., Nagashima, K. et al. Morphological and molecular course of mitochondrial pathology in cultured human cells exposed long-term to Zidovudine. Environ. Mol. Mutagen. 48, 179-189 (2007).
76. Maagaard, A. & Kvale, D. Long term adverse effects related to nucleoside reverse transcriptase inhibitors: Clinical impact of mitochondrial toxicity. Scand. J. Infect. Dis. 41, 808-817 (2009).
77. Haubrich, R. H., Riddler, S. A., DiRienzo, A. G., Komarow, L., Powderly, W. G., Klingman, K. et al. AIDS Clinical Trials Group (ACTG) A5142 Study Team. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitorsparing regimens for initial HIV treatment. AIDS 23, 1109-1118 (2009).
78. El Hadri, K., Glorian, M., Monsempes, C., Dieudonné, M. N., Pecquery, R., Giudicelli, Y. et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J. Biol. Chem. 279, 15130-15141 (2004).
79. Blas-Garcia, A., Apostolova, N., Ballesteros, D., Monleón, D., Morales, J. M., Rocha, M. et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 52, 115-125 (2010).
80. Ranade, K., Geese, W. J., Noor, M., Flint, O., Tebas, P., Mulligan, K. et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS 22, 1561-1568 (2008).
81. Ryden, M. & Arner, P. Tumour necrosis factor-alpha in human adipose tissue - from signaling mechanisms to clinical implications. J. Intern. Med. 262, 431-438 (2007).
82. Sevastianova, K., Sutinen, J., Kannisto, K., Hamsten, A., Ristola, M. & Yki-Ja rvinen, H. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am. J. Physiol. Endocrinol. Metab. 295, E85-E91 (2008).
83. Hadigan, C., Borgonha, S., Rabe, J., Young, V. & Grinspoon, S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 51, 1143-1147 (2002).
84. Villarroya, F., Domingo, P. & Giralt, M. Drug-induced lipotoxicity: Lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochim. Biophys. Acta 1801, 392-399 (2010).
85. Shrivastav, S., Kino, T., Cunningham, T., Ichijo, T., Schubert, U., Heinklein, P. et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: Implications for HIV-associated lipodystrophy. Mol. Endocrinol. 22, 234-247 (2008).
86. Garg, A. Lipodystrophies. Am. J. Med. 108, 143-152 (2000).